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Peripheral blood lymphocytes from 14 adult male patients admitted to the hospital 
with complications of intravenous drug abuse (IDA) were examined for natural killet 
(NK) and antibody-dependent cellular cytotoxic (ADCC) activities. lectin-dependent 
cellular cytotoxicity. and interferon (IFN)- and interleukin 2 (IL-2).induced NK acttvtty. 
Serum was also assayed for circulating interferon levels and soluble factor(s) capable of 
suppressing the cytotoxic potential of allogeneic lymphocytes from healthy donors. IDA 
patients demonstrated significantly decreased levels of NK and ADCC activities com- 
pared to age- and sex-matched healthy controls. The lectin. phytohemagglutinin. could 
significantly enhance the cytotoxicity of IDA lymphocytes: however. activity was not 
completely restored to normal levels. IDA sera demonstrated a significant inhibitory 
effect on the NK and ADCC activities of normal allogeneic lymphocytes, and these sera 
contained negligible levels of circulating 1FN. Although the NK activity of IDA lym- 
phocytes could not be restored completely to normal levels by either IFN-a or II.-2. 
the percentage enhancement of cytotoxicity was remarkably higher in IDA patients with 
significantly reduced NK activity than that observed using PBL from patients with neai 
normal NK activity. The ability of IFN or IL-2 to enhance the decreased cytotoxicity. 
of PBL from drug abusers suggests a novel therapeutic approach to the management of 
the complications of IDA. B 1% Academic Pren. Inc. 
INTRODUCTION 
The principal victims of acquired immunodeficiency syndrome (AIDS) have 
been male homosexuals, Haitian immigrants, hemophiliacs, and drug abusers ( l- 
14). AIDS is characterized by profound deficiency of cell-mediated immune re- 
sponses and selective abnormalities of immunoregulation (2, 5, 6, 1 I. 12, IS- 17). 
Many similar immunologic abnormalities such as hypergammaglobulinemia, dif- 
fuse hyperplasia of lymphoid tissues, smooth muscle and lymphotoxic antibodies. 
reduced number of active rosette-forming T cells, marked depression of the lym- 
phoproliferative response to antigens and mitogens, alteration of T-lymphocyte 
subsets, cutaneous anergy, increased incidence of malignancy, lymphopenia, etc. 
have been observed in patients with narcotic addiction (18-24). The current in- 
vestigations were undertaken to determine the effect of prolonged abuse of intra- 
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venous drugs on NK and ADCC functions of lymphocytes. These studies dem- 
onstrate that peripheral blood lymphocytes of patients with a history of intrave- 
nous drug abuse (IDA) display significantly lower NK and ADCC activities than 
healthy age- and sex-matched control donors. 
METHODS 
Patients. Fourteen male patients ranging from 25 to 45 years old were selected 
from the Outpatient Clinics of the Wayne County (Mich.) General Hospital which 
serves portions of the greater Detroit metropolitan area. In addition to the intra- 
venous use of heroin, pentazocine HCl plus pyribenzamine, hydromorphone HCl, 
and cocaine, these patients often had a history of the abuse of other substances 
taken orally including: marijuana, various tranquilizers, amphetamines, halluci- 
nogens, and ethanol alone or in combinations. Because of extensive and indis- 
criminate drug usage, it is not possible to accurately tabulate the drug repertoire 
for any individual subject. The duration of drug abuse ranged from 2 to 17 years 
with an average of 12.5 years. Drug consumption persisted during the study pe- 
riod. As controls, 7 healthy age- and sex-matched volunteers were recruited from 
the students and staff of The University of Michigan. Peripheral blood from pa- 
tients and healthy donors was drawn into a plastic syringe containing heparin (20 
U/ml). Donors were apprised of the study and consents were obtained consistent 
with the policies of The University of Michigan and the National Institutes of 
Health. Confidentiality was maintained by using only coded designations. 
Isolation of lymphocytes. Peripheral blood mononuclear cells (PBMC) were 
isolated from heparinized venous blood on a Ficoll-Hypaque gradient using a 
modified method of Boyum (25). Blood was diluted with an equal volume of 
normal saline (0.85%) and centrifuged at 400g for 30 min at 18°C. The mononu- 
clear cell band was harvested, washed three times with saline, and resuspended 
in RPM1 1640 medium containing 25 mM Hepes buffer, 80 kg/ml gentamicin 
(Schering Corp., Kenilworth, N.J.), 300 kg fresh glutamine per ml and 10% FCS 
(complete medium). The viability of the cells was routinely greater than 98% as 
assessed by trypan blue dye exclusion. 
Removal of adherent cells. PBMC were suspended in complete medium and 
passed through a 7-ml column of Sephadex G-10 beads (Pharmacia Fine Chemi- 
cals, Piscataway, N.J.) equilibrated with the same medium to deplete adherent 
cells. After 45 min of incubation at 37”C, nonadherent cells (PBL,) were washed 
through with one bed volume of medium at 37°C. PBL were washed three times 
with RPM1 1640 medium and suspended in complete medium. Viability was al- 
ways greater than 95% as assessed by trypan blue dye exclusion. 
Preparation of tumor target cells. The human erythroleukemia cell line, K-562, 
was used as targets for NK cells. For the ADCC assay, we chose as targets an 
antibody-coated human B-cell leukemia line (SB) because of resistance to NK 
activity in a 4 hr 51Cr release assay. Tumor target cells were serially passaged in 
complete medium and used in cytotoxicity assays no more than 48 hr after the 
last passage. To O.&ml aliquots of complete medium containing 5 x lo6 washed 
tumor cells, 200 $i of 51Cr as sodium chromate (New England Nuclear, Boston, 
Mass.) was added. The cells were incubated at 37°C for 1 hr in a humidified 
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atmosphere of 5% CO, in air, with intermittent shaking. After incubation the cells 
were washed three times with complete medium and resuspended to a concen- 
tration of 2 X IO’ cells/ml. 
Assayfor NK activity. NK activity was measured in a direct “Cr release assay 
as previously described (26, 27). A fixed number of viable effector PBL in com- 
plete medium was added to triplicate cultures of s’Cr-labeled targets in V-bottom 
microtitration plates (Costar, Cambridge, Mass.). After centrifugation at 401: for 
2 min, they were incubated at 37°C in a humidified atmosphere of 5% CO1 in air. 
for 4 hr. At the end of incubation, the plates were centrifuged at 400g for 10 min 
and IOO-~1 quantities of supernates were removed from each well and counted in 
a Packard Model 593 gamma counter. Percentage cytotoxicity was calculated as: 
% cytotoxicity = 
experimental release - spontaneous release 
x 100. 
total release - spontaneous release 
where spontaneous release represents counts released from control wells con- 
taining only 2 x IO4 target cells, and total release represents counts obtained 
from an aliquot of 2 x IO4 target cells. 
Assay for ADCC. ADCC activity was determined as previously described (26, 
27). Briefly, 50 ~1 of varying concentrations df effector cells were added to 50 ~1 
of complete medium containing 5’Cr-labeled SB target cells and 100 ~1 of a 2 X 
10e4 dilution of rabbit anti-SB antisera previously found to yield maximum 
ADCC, Percentage ADCC was calculated as described above for NK activity 
with the following exceptions. Spontaneous release represents counts released in 
control wells containing effector cells, labeled SB target cells. and media instead 
of anti-SB antibodies. and total release represents counts obtained in an aliquot 
of 1 x lo4 51Cr-labeled SB target cells. The spontaneous release of target cells 
in the presence of anti-target antibodies without effecters was similar to the spon- 
taneous release of target cells in the presence of effector cells and media alone. 
Lentin-dependent cell-mediated cytotoxicity (LDCC) assay. The LDCC assay 
was carried out similar to the NK assay. Briefly, appropriate numbers of target 
and effector cells were added in V-bottom microtitration plates and various con- 
centrations of phytohemagglutinin-P (Difco Laboratories, Detroit, Mich.) 1. 2.5. 
and 5 pg/ml, were added to a final volume of 0.2 ml and incubated for 4 hr at 
37°C in a humidified 5% CO,/95% air incubator. Percentage LDCC activity was 
calculated as described for the NK activity and was compared with cytotoxicity 
observed with control cultures containing effector and target cells. Percentage 
cytotoxicity was calculated as: 
% cytotoxicity = 
experimental release - spontaneous release 
x 100, 
total release - spontaneous release 
where spontaneous release represents counts released from control wells con- 
taining 2 x lo4 target cells plus lectin and total release represents counts obtained 
from 2 x lo4 lysed target cells. 
Treatment of effector cells with sew. Both control and patients’ sera were heat 
inactivated in a 56°C water bath for 30 min and centrifuged at 10,OOOg for 1 hr. 
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The supernates were collected and used in the NK and ADCC assays. All sera 
were tested in the assays within a week of collection. To test the inhibition of 
cytotoxic effector cell functions by sera, 5 x lo5 cells/ml of complete medium 
were incubated separately with either control or patients’ serum at a final con- 
centration of 10% (V/V) for 24 hr in a 5% CO,/95% air incubator, washed, and 
tested for cytotoxicity. Viability of serum treated samples after incubation was 
always greater than 90%. Percentage cytotoxicity was calculated as described 
above for the NK assay. 
Interferon (ZFN). Partially purified human leukocyte IFN-o was obtained as a 
gift from Parke-Davis and Company (Detroit, Mich.). The sp act was 6.3 x IO4 
U/mg protein. IFN was diluted in RPM1 1640 medium and stored at - 70°C before 
use. 
Znterleukin 2 (X-2). Commercially available IL-2 (Electra-Nucleonics Labs, 
Inc., Silver Spring, Md.) was diluted in RPM1 1640 and stored at -70°C before 
use. IL-2 was purified from human peripheral blood leukocytes by several chro- 
matographic steps and is devoid of any lectin or IFN. The maximum NK aug- 
menting dose (10% final concentration) as previously determined, was used. 
Treatment of effector cells with IFN or IL-2. PBL (2 x 106/ml) were washed 
and suspended in 1 ml of RPM1 1640 + 5% FCS to which 500 U of IFN-(Y or 
10% (V/V) IL-2 previously found to yield maximal NK augmenting effect was 
added. The cultures were incubated for 24 hr at 37°C in a humidified atmosphere 
of 5% COz in air, washed twice, and resuspended in medium. Control cultures 
were treated identically with the exception that either IFN or IL-2 was not added. 
Viability of treated lymphocytes was unaffected as assessed by trypan blue dye 
exclusion. Both treated and control cultures were assayed for NK activity. 
RESULTS 
Lymphocytes from IDA patients and healthy adults were tested against “Cr- 
labeled KS62 target cells in the NK assay and antibody-coated SB targets in the 
ADCC assay at effector to target (E:T) cell ratios varying from 100: 1 to 5: 1. 
(Tables 1 and 2). PBL from IDA patients displayed significantly decreased NK 
and ADCC activities against K562 and SB targets respectively, at all E:T cell 
ratios, compared to lymphocytes from age- and sex-matched healthy volunteers. 
Since IDA lymphocytes demonstrated reduced NK and ADCC activities, we 
examined whether IDA lymphocytes could be activated by lectin. The data 
prsented in Table 3 demonstrate that control lymphocytes at an E:T cell ratio of 
50: 1 produced 29.3 (P < 0.005) and 25.7% (P < 0.005) LDCC activity against SB 
targets at 1 and 2.5 pg/ml of PHA, respectively, compared to 4.2% cytotoxicity 
observed in the absence of PHA. PBL from IDA patients showed 3% cytotoxicity 
without PHA which was significantly enhanced to 15.7 (P < 0.005) and 15.9% (P 
< 0.01) by PHA at 1 and 2.5 p.g/ml concentrations, respectively. Lectin at an 
increased concentration of 5 kg/ml also resulted in increased cytotoxicity by both 
control (19.7%) (P < 0.005) and IDA lymphocytes (14%) (P < 0.05). Although 
PHA addition could considerably enhance the cytotoxicity of IDA lymphocytes, 
activity was not completely restored to levels shown by control lymphocytes. 
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TABLE I 
NK ACIIVI~Y OF LYMPHOCYTES FROM HEALTHY DONOKS AND IN~RAL~NO~S DKCG ABULKS :\I 






I Controls 42.8 2 3.8 
IDA 31.5 -t X.2 
-7 Controls 53.4 i X.2 
IDA 29.6 t 5.9 
3 Controls 48.1 t 5.6 
IDA 25.5 t 7.x 
4 Controls” 52.4 2 7.1 
IDA 18.6 t I.0 
P < 0.005~ 
E:T cell ratios 
” Effector cells were depleted of phagocytic cells. by passage through a G-IO column. KF62 target 
cells were labeled with “Cr as detailed under Methods. Values represent mean percentage cytotoxicity 
2 SD for each experiment. A total of 7 controls and I4 IDA samples were examined in four Teparatc 
experiments with triplicate determinations. Each experiment employed 2 to 4 IDA and I to 2 control 
samples. 
h Only one control was employed in this experiment and values represent mean i SD of triplicate 
determinations of that sample. 
’ Statistical values were determined by a z-way analysis of variance using an F test to account ~L)I 
the day to day experimental variations of cytotoxicity. 
For example, control lymphocytes demonstrated 29.3 and 25.7% LDCC com- 
pared to significantly decreased cytotoxicity lS.7c% (P < 0.01) and 15.9% (P c 
0.05), shown by IDA lymphocytes at 1 and 2.5 pgiml concentrations of PHA. 
respectively. 
We investigated whether human leukocyte interferon-a or interleukin 2 could 
activate or restore the depressed cytotoxicity of IDA lymphocytes against K562 
target cells. Data presented in Fig. 1 demonstrate that control PBL precultured 
with either IFN-(w or IL-2 show significant enhancement of their NK activity, 
i.e., 58.4% (P < 0.01) and 68.3% (P < 0.007). respectively, compared to 42.5% 
cytotoxicity shown by untreated control cultures. Patient groups were separated 
into “moderate” and “reduced” NK activity. The former represents cytotoxic 
activity within 2 standard deviations (SD) below the mean for controls whereas 
the latter includes all individuals whose NK activity was less than 2 SD below 
the mean control value. IDA lymphocytes which demonstrated only slightly de- 
creased or moderate NK activity (34.2%) compared to control lymphocytes 
(42.5%) displayed a significant enhancement of their NK activity when treated 
with either IFN-(w (46.8%; P < 0.01) or IL-2 (50.0%; P < 0.01) in comparison to 
untreated control cultures (34.2%). PBL from IDA patients which showed highly 
depressed NK activity (20.0%) also manifested significant enhancement of their 
cytotoxic potential when incubated with IFN-a (34.0%; P < 0.01) or IL-2 (52.4%; 
P < 0.001). The percentage enhancement of both IFN-a and IL-2-induced cy- 
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TABLE 2 
ADCC ACTIVITY OF LYMPHOCYTES FROM HEALTHY DONORS AND INTRAVENOUS DRUG ABUSERS AT 
VARYING EFFECTOR TO TARGET CELL RATIOSO 
E:T cell ratios 
Expt 
Lymphocyte loo:1 5O:l 25:l 5:1 










38.2 k 8.2 
21.1 2 10.8 
51.2 2 6.2 
24.9 k 3.0 
49.2 2 3.7 
32.0 f  10.9 
51.4 t 4.8 
20.6 2 1.2 
P < 0.005 
36.7 2 6.7 
19.6 ” 7.6 
47.2 k 7.1 
21.3 k 2.1 
45.2 2 4.8 
29.0 2 11.1 
47.6 t 5.6 
17.7 i- 5.3 
P e 0.01 
23.8 2 3.4 
13.9 k 5.6 
29.2 ” 5.6 
10.7 r 2.3 
32.1 + 3.4 
12.0 t 3.8 
28.7 2 4.2 
9.3 2 2.1 
P < 0.006 
10.8 2 1.8 
6.8 k 2.0 
24.2 2 4.1 
11.0 t 9.4 
18.2 2 1.8 
8.3 2 4.5 
17.2 2 1.9 
5.8 k 0.6 
P < 0.02 
0 Effector cells were depleted of phagocytic cells by passage through a G-10 column and SB target 
cells were labeled with 51Cr as detailed under Methods. Values represent mean percentage cytotoxicity 
-t SD in each experiment. A total of 7 controls and 14 IDA samples were examined in four separate 
experiments with triplicate determinations. Each experiment employed 2 to 4 IDA and 1 to 2 control 
samples. 
’ Only one control was employed in this experiment and values represent mean 2 SD of triplicate 
determinations. 
c Statistical values were determined by a 2-way analysis of variance using F test to account for the 
day to day experimental variation of cytotoxicity. 
totoxicity (136 and 147%, respectively) of IDA lymphocytes which demonstrated 
moderate NK activity was comparable with IFN-cx (137%) and IL-2 (160%)- 
induced enhancement of control PBL. IDA lymphocytes which showed very re- 
duced NK activity demonstrated greater percentage enhancement of IFN-(Y 
(170%)- and IL-2 (262%)-induced cytotoxicity compared to enhancement of either 
TABLE 3 
EFFECT OF LECTIN ON CELLULAR CYTOTOXICITY OF IDA LYMPHOCYTES” 





0 I 2.5 5 
% Cytotoxicity” 
4.2 -r- 1.8’ 29.3 2 4.5 25.7 k 3.8 19.7 2 3.1 
(P < O.OOS)d (P < 0.005) (P i 0.005) 
3.0 -+ 0.9 15.7 2 2.3 15.9 t 3.7 14.0 2 4.9 
(P < 0.005) (P < 0.01) (P < 0.05) 
U The lectin-dependent cellular cytotoxicity (LDCC) assay was carried out similar to the NK assay 
except the NK resistant SE cell line was used as targets as described under Methods. 
b Percentage cytotoxicity was calculated as described under Methods. 
( Values represent mean percentage cytotoxicity k SD of three separate experiments performed in 
a single day to avoid experimental variation employing three normal controls and three patients. 
Experiments were performed in triplicate at a 50: 1 effector to target cell ratio. 
d Statistical values were determined by 2-sample t tests on differential scales. 







NK activity NK actbvity 
FIG. I. Effect of IFN and IL-2 on NK activity. PBL depleted of adherent cell\ were precultured 
with IFN (500 U) or 11*-Z ( 10% V/V). previously found to yield maximal NK augmenting effect. for 
24 hr at 37°C. washed and tested for NK activity against prelaheled K562 target cells at a SO: I effector 
to target cell ratio. Patient groups were separated into “moderate” and “reduced” NK activity. The 
former represents cytotoxic activity within 2 standard deviations below the mean for controls wherea\ 
the latter includes all individuals whose NK activity was less than 2 SD beloti the mean control 
value. The viability of lymphocytes precultured with either IFN or IL-2 wa\ somparahle with that of 
control cultures and was found to be > 85% as assessed by vital dye exclusion. Results are exprehhed 
as mean percentage cytotoxicity k SD of four separate experiments performed in triplicate. Each 
experiment included one patient and one control. The statistical significance of differences in mean 
values was determined using a paired t test formula. 
IDA lymphocytes with moderately reduced NK activity (136 and 147%,. respec- 
tively, for IFN-a and IL-21 or control lymphocytes ( 137 and 160%. respectively. 
for IFN-a and IL-2). Thus, although the cytotoxicity could not be restored com- 
pletely to normal levels, the percentage enhancement of cytotoxicity by IFN-cu 
or IL-2 was remarkably higher in IDA patients with highly depressed cytotoxic 
functions. 
Studies by ourselves (28) as well as others (29) demonstrated that normal sera 
contains suppressive factors directed against NK and ADCC functions of normal 
autologous and allogeneic lymphocytes, and these factors are significantly higher 
in sera from a variety of cancer patients. We investigated the ability of IDA sera 
for their suppressive effect on NK and ADCC activities of allogeneic lymphocytes 
from control donors. The data presented in Fig. 2, show that allogeneic normal 
lymphocytes precultured with normal human sera produce 41.5% NK activity 
compared to significantly decreased cytotoxicity (23.2%: P < 0.05) shown by the 
same lymphocytes precultured with IDA sera. In the ADCC assay. allogeneic 
lymphocytes precultured with normal human sera demonstrated 3 I .6% cytotox- 
icity compared to significantly reduced cytotoxicity (10.5%; P < 0.01) displayed 
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II Normal sera 
IDA sera 
FIG. 2. Inhibition of NK and ADCC activities of allogeneic normal PBL by control and IDA sera. 
All set-a were heat treated at 56°C for I hr and tested at a 10% (V/V) final concentration in the assay. 
A total of five individual sera were examined separately in each group in a single day to avoid 
experimental variation. Mean percentage inhibition k SD is presented. The experiments were done 
in triplicate at a 5O:l effector to target cell ratio. The statistical significance of differences in mean 
values was determined using a paired t test formula. 
by lymphocytes precultured with IDA sera. All IDA serum samples tested dem- 
onstrated some inhibition ranging from 15 to 52%. 
Experiments were carried out to investigate whether circulating serum IFN 
was responsible for the suppressed NK and ADCC activity observed in IDA 
patients. Circulating serum IFN levels in controls as well as IDA patients were 
negligible except one patient who demonstrated a significantly increased level of 
IFN (1760 U/ml) (data not presented). Interestingly, PBL from this patient showed 
moderate levels of NK activity (32%) and his lymphocytes failed to demonstrate 
significant enhancement (38% cytotoxicity, 18% enhancement) of NK activity 
when pretreated with IFN-c~ in vitro (data not presented). This latter observation 
suggests that endogenous serum IFN levels may modulate NK activity in vivo 
and in certain patients, elevated IFN levels may make their PBL resistant to 
further enhancement of NK activity with exogenous IFN. 
DISCUSSION 
Recent evidence suggests that NK cells represent a first line of defense against 
spontaneously developing neoplasms (26, 30-35). Patients with cancer and AIDS 
exhibit significantly lower levels of NK activities than control donors, potentially 
predisposing them to progressive disease. Many reports suggest that parenteral 
drug abusers are at an increased risk of developing AIDS and other immunologic 
abnormalities have also been observed in patients with narcotic addiction (5, 6, 
12, 14- 16. 18-22, 24). We report herein that lymphocytes from intravenous drug 
abusers display significantly decreased NK and ADCC activities against KS62 
and SB target cells, respectively, compared to age- and sex-matched healthy 
controls. Because of the indiscriminate and extensive use of several drugs in a 
variety of ways, the effect seen in these patients cannot be correlated with any 
particular substance. The reduced NK and ADCC activities observed in IDA 
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patients are consistent with reports demonstrating similar findings in AIDS pa- 
tients (13). 
NK cells appear to have some selectivity since certain targets are very sus- 
ceptible whereas others are resistant. This may be due to differences in the 
antigenic structures present on target cells or the receptor sites on NK cells or 
both. It has been demonstrated that lymphocyte cytotoxicity can be activated by 
lectin (PHA). The exact mechanism of lectin activation is not presently under- 
stood. but it has been suggested that it may act directly on cytotoxic cells by 
rearranging cryptic receptors for recognition sites on target cells. providing suf- 
ficient signals to trigger subsequent lytic events (37. 38). In the present report it 
was demonstrated that the cytotoxicity of IDA lymphocytes could be consider- 
ably enhanced by PHA even though cytotoxicity could not be restored to normal 
levels (Table 3). 
Sera from cancer patients appear to contain factors capable of inhibiting NK 
and ADCC reactions (28, 29). Analysis of serum factors that can inhibit NK and 
ADCC activities may thus be relevant to host resistance to tumor growth. Re- 
cently several reports demonstrated that sera from AIDS patients blocked normal 
lymphocyte responses and IFN-induced NK activity (8. 30. 31). In the present 
investigation sera from IDA patients showed significant inhibitory effects on NK 
and ADCC functions of control lymphocytes compared to normal sera (Fig. 3). 
This suppressive effect of IDA sera was not due to altered target susceptibility 
since the viabihty of target cells pretreated with IDA sera was comparable to that 
of targets pretreated with control sera (data not presented). Further the effect 
was due not to dilution, since identical aliquots of normal human sera were alway\ 
used as control. The suppressive activity of IDA sera showed a dose-dependent 
effect. When two different IDA serum samples were tested at I, 5. and 10% (voli 
vol) final concentration in 10% fetal calf serum. they exhibited proportionally- 
greater suppression of cytotoxicity with increasing concentration compared to 
normal donor serum (data not shown). Thus, immunodeficiency in IDA may be 
associated with the development of soluble serum suppressor factors. The ability 
of IDA serum to inhibit the NK and ADCC activities of lymphocytes it? ~~if,w may 
reflect similar inhibitory effects on NK and ADCC effector cells irr I,~I,c). Increase 
in soluble inhibitory activity in the sera of IDA patients may predispose them 1~ 
various infections and possibly to malignancy. 
IFN has been used as a stimulator of NK cell activity in ri\,o and i/z \‘itro. The 
mechanism of NK activation by IFN remains to be determined. IFN may activate 
noncytotoxic pre-NK cells to mature cytotoxic effector cells (38-40) or activate 
mature NK cells that are transiently inactive or potentiate endogenous lytic mech- 
anisms by developing new receptors or modulating preexisting cell surface mol- 
ecules or their avidity (39-42). However, it has been suggested that IFN may be 
particularly effective in patients with a sufficient number of target specific pre- 
cursors of natural killer cells (38, 43. 44). Rook et al. (13) demonstrated that IFN 
could not activate the cytotoxic potential of lymphocytes from AIDS patients but 
this activity could be enhanced with IL-2. Recently Reddy and co-workers (45) 
also demonstrated that NK activity could be enhanced with IL-2 in homosexual 
men with AIDS. Krown and her associates (46) have demonstrated that recom- 
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binant human leukocyte IFN was capable of inducing tumor regression in patients 
with Kaposi’s sarcoma. DeStefano et al. (47) showed the presence of an acid- 
labile IFN in AIDS patients’ sera which may be responsible for the lack of NK 
cell responsiveness to exogenous IFN. 
A number of mechanisms may be involved in the IL-2-induced enhancement 
of NK activity, including the ability of IL-2 to expand the immunoreactive helper 
and effector clones of NK cells, induce more target recognition structures on NK 
cells, activate precursor cytotoxic cells, increase the production of natural killer 
cytotoxic factor and/or hasten the recycling phase of the effector cells. Others 
have shown that NK cells are themselves capable of secreting IFN (48) and a 
critical role of IL-2 in the production of IFN has been proposed (49,50). Therefore 
it is conceivable that IL-2 may stimulate production of IFN, which alone or 
synergistically with IL-2, may subsequently enhance the NK activity of lympho- 
cytes. Watson et al. (51) proposed that IL-2 could replace helper cell functions 
and therefore was important in cytotoxic mechanisms. The present investigation 
demonstrates that both NK and ADCC activities of lymphocytes from IDA pa- 
tients are depressed, but these activities could be significantly enhanced by treat- 
ment with IFN and IL-2 (Fig. 1). The degree of augmentation of NK activity with 
IFN and IL-2 was particularly higher in IDA patients who displayed the lowest 
endogenous NK activities. The increased cytotoxicity of IDA lymphocytes in- 
duced by PHA, IFN, and IL-2 also suggests that LDCC precursors and lym- 
phokine-responsive NK precursors were normal, while active NK effecters may 
have been deficient in IDA patients. Further studies employing single cell assays 
with Percoll-enriched effector cells to examine target binding and the post binding 
phases of NK cell activity, the maximum recycling capacity to lyse target cells, 
and the production of natural killer cytotoxic factor, IFN, and IL-2 by IDA lym- 
phocytes will help to delineate the cytotoxic dysfunctions in IDA. patients. The 
sera of live of six IDA patients demonstrated negligible levels of circulating IFN 
suggesting that exogenous IFN could possibly potentiate the lyt ic capacity of 
patients’ PBL comparable to normal lymphocytes. Therefore immunomodulation 
with IFN or IL-2 may hold promise for developing a unique immunotherapeutic 
approach to the management of the complications of IDA. 
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